Type 2 diabetes Chronic kidney disease pioglitazone type 2 diabetes chronic kidney disease fluid retention
Conditions
Interventions
Oral pioglitazone 15 mg/day,Oral pioglitazone 7.5 mg/day
Active Comparator Drug,Active Comparator Drug
standard dose pioglitazone,low dose pioglitazone
Sponsors
Phramongkutklao Hospital and College of Medicine
Phramongkutklao Hospital and College of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age 18 years or older, diagnosed T2DM with stable glycemic treatment with HbA1c>8% at least 12 weeks and diagnosed CKD according to Kidney Disease: Improving Global Outcomes (KDIGO) 2012 definition and no history of treatment with pioglitzone within 12 weeks before starting the study.
Exclusion criteria
Exclusion criteria: active malignancy, severe heart, lung or liver disease, stroke, chronic infection, e.g., tuberculosis within one year of starting the study, limited life expectancy within 12 months, edematous state from any cause and specific contra-indications to pioglitazone including increased serum levels of liver enzyme (aspartate aminotransferase [AST] or alanine aminotransferase [ALT] >2.5 times the upper limit of normal), and history of bladder malignancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| hemoglobinA1c 24 weeks blood test,Body composition 24 weeks bio-electrical impedance analysis | — |
Secondary
| Measure | Time frame |
|---|---|
| Body composition 24 weeks bio-electrical impedance analysis | — |
Countries
Thailand
Contacts
Public ContactBancha Satirapoj
Phramongkutklao Hospital and College of Medicine
Outcome results
None listed